Imaging and diagnostic solutions provider Neurovision Imaging LLC has raised financing for regulatory approval of its retinal imaging technology for the early detection and monitoring of Alzheimer’s-related amyloid pathology. The company’s imaging technology focuses on the retina, a developmental outgrowth of the central nervous system sharing many of the brain's characteristics, enabling the potential of retinal imaging for amyloid detection in Alzheimer's disease. The Series B financing was led by a $5 million investment from Wildcat Capital Management. A portion of the funds is being reserved for strategic investors. Leonard Potter, chief investment officer and president of Wildcat Capital Management, has been named to Neurovision’s board of directors.